Robert Terkola

Robert Terkola is a researcher at the University of Groningen specializing in oncology, pharmacology, and healthcare efficiency. His work directly contributes to UN Sustainable Development Goals for health and well-being, with a focus on improving cancer care delivery through evidence-based interventions. He completed his PhD at the University of Groningen in 2025, establishing expertise in pharmaceutical safety and healthcare economics.

Research Focus

Dr. Terkola's investigations target critical gaps in cancer treatment: prevention of medication errors during chemotherapy preparation, microbiological contamination control in sterile environments, and cost-effectiveness analysis of supportive care agents. His fingerprint analysis reveals dominant activity in malignant neoplasms (100%), oncology (66%), chemotherapy (53%), and medication error prevention (42%), demonstrating interdisciplinary integration of clinical oncology, pharmaceutical science, and health policy.

Publication Trends

His recent publications (2022-2025) reveal a strategic shift toward real-world data applications for optimizing cancer care value. Key themes include closed-system drug transfer device validation, granulocyte colony-stimulating factor cost-benefit analysis, and European quality standards for glioma treatment. These works consistently bridge laboratory research with healthcare system implementation, emphasizing affordability without compromising safety.

Collaborative Impact

• International contributions to European Cancer Organisation guidelines
• High-impact publications with significant citation metrics (e.g., 7 Scopus citations for glioma editorial)
• Active research network spanning multiple countries as shown in collaboration mapping
• Integration of pharmacological safety with health economics frameworks